Liver X receptor is a therapeutic target in collagen‐induced arthritis

Saved in:
Bibliographic Details
Published inArthritis and rheumatism Vol. 56; no. 4; pp. 1365 - 1367
Main Authors Chintalacharuvu, Subba R., Sandusky, George E., Burris, Thomas P., Burmer, Glenna C., Nagpal, Sunil
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.04.2007
Wiley
Subjects
Animals
Antirheumatic Agents - therapeutic use
Arthritis, Experimental - drug therapy
Arthritis, Experimental - metabolism
Arthritis, Experimental - pathology
Biological and medical sciences
Cytokines - metabolism
Disease Progression
Diseases of the osteoarticular system
DNA-Binding Proteins - metabolism
Dose-Response Relationship, Drug
Drug Therapy, Combination
Female
Humans
Hydrocarbons, Fluorinated
Inflammatory joint diseases
Lipopolysaccharides - pharmacology
Liver X Receptors
Medical sciences
Mice
Mice, Inbred BALB C
Orphan Nuclear Receptors
Receptors, Cytoplasmic and Nuclear - metabolism
Sulfonamides - therapeutic use
Synovial Membrane - drug effects
Synovial Membrane - metabolism
Synovial Membrane - pathology
Immunopathology
Chronic
Treatment
Liver
Rheumatoid arthritis
Diseases of the osteoarticular system
Rheumatology
Autoimmune disease
Inflammatory joint disease
Online AccessGet full text

Cover

More Information
Bibliography:Dr. Burris has received consulting fees and honoraria from Orphagen Pharmaceuticals, Invitrogen, GTx, Inc. (less than $10,000 each), Eli Lilly and Company, and Phenex Pharmaceuticals (more than $10,000 each). Dr. Burris holds stock or stock options in Eli Lilly and Company and Orphagen Pharmaceuticals.
Dr. Nagpal holds stock or stock options in Eli Lilly and Company, Allergan, and Wyeth, and holds patents on retinoids and vitamin D analogs.
ISSN:0004-3591
1529-0131
DOI:10.1002/art.22528